AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELY IMMUNOCOMPROMISED
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELY IMMUNOCOMPROMISED
This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized at baseline with mild-to-moderate COVID-19.
The purpose of this clinical trial is to learn about a study medicine called Ibuzatrelvir for the possible treatment of COVID-19 in immunocompromised patients. Immunocompromised patients with COVID-19 have more difficulty fighting infections and are at risk for persistent infections and progression to severe illness. This patient population may benefit from extended antiviral treatment durations, or a combination of antiviral therapies. This study will evaluate the efficacy and safety of ibuzatrelvir with and without remdesivir compared with remdesivir alone for the treatment of symptomatic COVID-19 in adult participants who are severely immunocompromised.
The study is seeking adult male and female participants who:
All of the participants in this study will receive active treatment for COVID-19, and will be randomized to one of three treatment arms. One-third will received remdesivir, one-third will receive ibuzatrelvir, and one third will receive both remdesivir and ibuzatrelvir. Ibuzatrelvir will be taken by mouth twice daily, and remdesivir is given as an IV infusion daily. Placebos that look like the study medicines but do not have any medication will be given to make the 3 treatment arms appear to be the same. The study will compare the experiences of people receiving ibuzatrelvir with and without remdesivir to those of the people who only received remdesivir for COVID-19. This will help decide if ibuzatrelvir is safe and effective.
Participants will attend about 10 study visits over 24 weeks. During this time, they will have:
Inclusion Criteria:
18 years of age or older at screening who are non-hospitalized or hospitalized with mild to moderate COVID-19
Confirmed SARS-CoV-2 infection as determined by RAT (or other locally approved test) collected within 2 days prior to randomization. Initial onset of symptoms attributable to COVID-19 within 5 days prior to the day of randomization and at least 1 of the specified symptoms attributable to COVID-19 present on the day of randomization.
Severely immunocompromised due to:
Exclusion Criteria:
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Aurora, Colorado 80045, United States
Aurora, Colorado 80045, United States
Washington D.C., District of Columbia 20007, United States
Worcester, Massachusetts 01655, United States
Cincinnati, Ohio 45267, United States
Charleston, South Carolina 29425, United States
Charleston, South Carolina 29425, United States
Charleston, South Carolina 29425, United States
Charleston, South Carolina 29425, United States
Charleston, South Carolina 29425, United States
Dallas, Texas 75246, United States
Dallas, Texas 75246, United States
Houston, Texas 77030, United States
Seattle, Washington 98104, United States
ABB, Buenos Aires F.D. C1199ABB, Argentina
Brussels, Bruxelles-capitale, Région de 1070, Belgium
Belo Horizonte, Minas Gerais 30130-100, Brazil
Bairro Santa Cecília, Rio Grande do Sul 90630-165, Brazil
Rio de Janeiro, 21040-360, Brazil
São Paulo, 05652-900, Brazil
Dijon, 21000, France
Alexandroupoli, Anatolikí Makedonía KAI Thráki 681 00, Greece
Narita, Chiba 286-8520, Japan
San Pedro Garza García, Nuevo León 66278, Mexico
Mexico City, 14080, Mexico
Banská Bystrica, Banská Bystrica Region 974 01, Slovakia
Namdong-gu, Incheon-gwangyeoksi [incheon] 21565, South Korea
Seoul, Seoul-teukbyeolsi [seoul] 03312, South Korea
A Coruña, A Coruña [LA Coruña] 15006, Spain
Gaziantep, 27310, Turkey (Türkiye)